Researchers found that a new implantable device for continuous blood glucose monitoring (CBGM) could significantly improve diabetes management. This device, developed by Glucotrack, Inc., has shown promising results in a study involving sheep, where it maintained accurate glucose readings over a period of up to 240 days. The study reported an impressive average accuracy rate, with a Mean Absolute Relative Difference (MARD) of just 6.8%, indicating that the device can reliably track blood sugar levels without the need for frequent calibration.

For people living with diabetes, this technology could mean fewer finger pricks and a more convenient way to monitor blood sugar levels. The device is designed to be implanted long-term, offering a potential solution for those who struggle with traditional glucose monitoring methods. With a sensor lifespan of up to three years, users could enjoy a more stable and less intrusive monitoring experience, ultimately leading to better health outcomes and improved quality of life.

The evidence comes from a study on an animal model, specifically sheep, which is an early-stage evaluation. While the results are encouraging, they have not yet been tested in humans on a large scale. Glucotrack is preparing to submit this technology for regulatory approval, which is a crucial step before it can be made available to the public. Therefore, while the findings are promising, further research and clinical trials are needed to confirm its effectiveness and safety in humans.

If you’re interested in managing your blood sugar more effectively, staying informed about advancements like this implantable glucose monitor could be beneficial. As technology evolves, it may soon offer new options for diabetes care that could enhance your daily life.

Source: globenewswire.com